Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for polyarticular juvenile rheumatoid arthritis has been reported in the published literature.
No clinical trials have been registered for polyarticular juvenile rheumatoid arthritis.
47 publications have been identified in PubMed for polyarticular juvenile rheumatoid arthritis. Research spans Epidemiology / Natural History (40%), Clinical Trial Publication (17%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 19 | 40% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 3:07 PM UTC
Clinical study results |
8 |
17% |
Research summaries | 7 | 15% |
Patient case studies | 7 | 15% |
Testing and diagnosis research | 4 | 9% |
Laboratory research | 2 | 4% |
Liu P (2026). [PMID: 41557167](https://pubmed.ncbi.nlm.nih.gov/41557167/). *Clin Rheumatol*. [Epidemiology / Natural History]
Abedeen ZU (2026). [PMID: 41578476](https://pubmed.ncbi.nlm.nih.gov/41578476/). *Medicine (Baltimore)*. [Case Report / Case Series]
Cunningham C (2026). [PMID: 41801091](https://pubmed.ncbi.nlm.nih.gov/41801091/). *Arthritis Care Res (Hoboken)*. [Epidemiology / Natural History]
Okamoto Y (2026). [PMID: 42266057](https://pubmed.ncbi.nlm.nih.gov/42266057/). *Curr Opin Rheumatol*. [Review / Meta-Analysis]
Yildiz M (2026). [PMID: 41621940](https://pubmed.ncbi.nlm.nih.gov/41621940/). *J Rheumatol*. [Clinical Trial Publication]
Thatayatikom A (2026). [PMID: 32119492](https://pubmed.ncbi.nlm.nih.gov/32119492/). *Unknown Journal*. [Review / Meta-Analysis]
Zhou Y (2026). [PMID: 41974575](https://pubmed.ncbi.nlm.nih.gov/41974575/). *Zhejiang Da Xue Xue Bao Yi Xue Ban*. [Epidemiology / Natural History]
Ito A (2025). [PMID: 39470373](https://pubmed.ncbi.nlm.nih.gov/39470373/). *Mod Rheumatol Case Rep*. [Case Report / Case Series]
Naddei R (2025). [PMID: 40108689](https://pubmed.ncbi.nlm.nih.gov/40108689/). *Pediatr Rheumatol Online J*. [Epidemiology / Natural History]
Tardão GC (2025). [PMID: 40688782](https://pubmed.ncbi.nlm.nih.gov/40688782/). *Int J Ophthalmol*. [Diagnostic / Biomarker]
AI-curated news mentioning polyarticular juvenile rheumatoid arthritis
Updated Sep 10, 2026
Researchers developed a new humanized TCR transgenic mouse model to study T cells that react to citrullinated tenascin C, an important autoantigen in rheumatoid arthritis. This model could enhance understanding of the disease mechanisms and potential therapeutic targets.
A case study highlights the occurrence of a giant abdominal hematoma and rapid multidrug-resistant infection in a patient with COVID-19 and rheumatoid arthritis following low-molecular-weight heparin treatment. This finding underscores potential complications in managing anticoagulation in patients with complex comorbidities.
A multicenter observational study by GIRRCS evaluates the effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis. The findings contribute to the understanding of real-life outcomes for this treatment class.
Rise Therapeutics has completed enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial for R-2487 in patients with active rheumatoid arthritis. This advancement allows for further evaluation of the therapy, with data expected to be presented at upcoming rheumatology and immunology conferences.